Multiple roles of CD90 in cancer

THY1 (CD90) is a 25–37-kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein. It is usually expressed on thymocytes, mesenchymal stem cells, hematopoietic stem cells, natural killer cells, neurons, endothelial cells, renal glomerular mesangial cells, follicular de...

Full description

Saved in:
Bibliographic Details
Published inTumor biology Vol. 37; no. 9; pp. 11611 - 11622
Main Authors Kumar, Atul, Bhanja, Anshuman, Bhattacharyya, Jina, Jaganathan, Bithiah Grace
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 01.09.2016
Springer Nature B.V
Subjects
Biomarkers
Biomarkers, Tumor
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cancer therapies
Humans
Medical prognosis
Metastasis
Neoplasm Metastasis
Neoplasms - etiology
Neoplasms - pathology
Review
Stem cells
Stromal Cells - chemistry
Thy-1 Antigens - analysis
Thy-1 Antigens - genetics
Thy-1 Antigens - physiology
Tumor Suppressor Proteins - physiology
Therapy
Biomarker
Prognosis
CD90
Stem cells
Metastasis
Microenvironment
Cancer
Online AccessGet full text

Cover

More Information
Summary:THY1 (CD90) is a 25–37-kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein. It is usually expressed on thymocytes, mesenchymal stem cells, hematopoietic stem cells, natural killer cells, neurons, endothelial cells, renal glomerular mesangial cells, follicular dendritic cells, fibroblasts, and myofibroblasts. It has been found to regulate cell adhesion, migration, apoptosis, axon growth, cell-cell and cell-matrix interactions, T-cell activation, and fibrosis. Several reports have shown that CD90 has an important role in cancer in regulating cancer cell proliferation, metastasis, and angiogenesis. There are also evidences that CD90 is an important prognostic marker in many cancers. Consequently, therapies that target CD90 have great promise in treating many cancers. However, several studies also indicate a contradictory role for CD90, where it acts as a tumor suppressor. In this review, we summarize the expression, function of CD90 in different cancers and its possible use as a biomarker or a therapeutic target in cancer. The challenges and future prospects for the use of CD90 for clinical applications are also discussed in this review.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-016-5112-0